Praxis Precision Medicines. has been granted a patent for compounds that target sodium channels, useful in treating neurological disorders like Dravet syndrome and epilepsy, as well as pain and neuromuscular disorders. The patent includes pharmaceutical compositions containing these compounds. GlobalData’s report on Praxis Precision Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Praxis Precision Medicines, Peptide pharmacophores was a key innovation area identified from patents. Praxis Precision Medicines's grant share as of June 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12030881B2 outlines a pharmaceutical composition that includes a compound represented by a specific chemical formula, along with a pharmaceutically acceptable carrier. The claims detail various forms of administration, including parenteral and oral routes, with specified dosage ranges. For parenteral administration, the composition can contain between 0.1 mg to 700 mg of the active compound or its salts, while for oral administration, the range is from 1 mg to 2 g. The composition can be formulated in multiple forms, such as tablets, powders, syrups, or ointments, and may contain up to 10% by weight of the active compound.
Additionally, the patent claims a method for treating conditions associated with the aberrant function of sodium ion channels, specifically targeting neurological and psychiatric disorders. The conditions mentioned include epilepsy and its various syndromes, such as genetic or pediatric epilepsy, as well as epileptic encephalopathy, which encompasses specific syndromes like Dravet syndrome, infantile spasms, and Lennox-Gastaut syndrome. The claims emphasize the therapeutic potential of the pharmaceutical composition in addressing these medical conditions through the administration of a therapeutically effective amount of the compound.
To know more about GlobalData’s detailed insights on Praxis Precision Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
